EXACT Therapeutics: Exercise of Warrants by GE Medical Holding ABGE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million.
EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancerOSLO, Norway, June 24, 2025 (GLOBE NEWSWIRE) -- EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce first patient dosed in its ENACT trial.
EXACT Therapeutics announces positive final results in Phase 1 ACTIVATE trial in liver metastases from colorectal cancerOSLO, Norway, May 20, 2025 (GLOBE NEWSWIRE) -- EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce the final and positive data set from its Phase 1 ACTIVATE trial. The trial investigated the use of EXACT’s proprietary Acoustic Cluster Therapy with chemotherapy in hard-to-treat patients with liver metastases of colorectal origin. These encouraging clinical data provide proof of principle for the clinical application of ACT technology and offer strong support for initiating the ENACT Phase 2 study in pancreatic cancer, a disease with a high unmet medical need.
